← Back to Search

Decision Aid for Psoriatic Arthritis and Psoriasis (DA Trial)

N/A
Waitlist Available
Led By Alexis Ogdie-Beatty, MD
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Initiation of a new psoriasis or psoriatic arthritis treatment
Age 18 years or older
Must not have
Youth, under the age of 18 years
Patients without psoriasis or psoriatic arthritis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will create and test a new way to help patients with psoriasis and/or psoriatic arthritis make decisions about their treatment.

Who is the study for?
This trial is for adults over 18 with psoriasis or psoriatic arthritis confirmed by a specialist, starting or switching to new FDA-approved treatments. It's only for patients treated at Penn clinics who can consent to participate.
What is being tested?
The study aims to develop and evaluate a decision aid tool designed to help patients with psoriasis or psoriatic arthritis make informed choices about their treatment options in collaboration with their healthcare providers.
What are the potential side effects?
Since the intervention is a decision aid tool rather than a medical treatment, there are no direct side effects associated with it. The focus is on improving the treatment decision-making process.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am starting a new treatment for psoriasis or psoriatic arthritis.
Select...
I am 18 years old or older.
Select...
I have been diagnosed with psoriasis or psoriatic arthritis by a specialist.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am younger than 18 years old.
Select...
I do not have psoriasis or psoriatic arthritis.
Select...
I am unable to understand and agree to the study's details on my own.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Patient and provider self-reported perceptions of the decision aid as measured by satisfaction survey
Secondary study objectives
Number of times decision aid was used in consultation for patients switching therapies or starting a new treatment.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Decision Aid TestingExperimental Treatment1 Intervention
Participants will have the opportunity to test the different decision aid prototypes while selecting new treatment/therapy.

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
2,077 Previous Clinical Trials
42,719,985 Total Patients Enrolled
11 Trials studying Psoriasis
2,698 Patients Enrolled for Psoriasis
PfizerIndustry Sponsor
4,658 Previous Clinical Trials
17,877,183 Total Patients Enrolled
67 Trials studying Psoriasis
172,487 Patients Enrolled for Psoriasis
Alexis Ogdie-Beatty, MDPrincipal InvestigatorUniversity of Pennsylvania
3 Previous Clinical Trials
427 Total Patients Enrolled
1 Trials studying Psoriasis
40 Patients Enrolled for Psoriasis

Media Library

Decision Aid Testing Clinical Trial Eligibility Overview. Trial Name: NCT03737045 — N/A
Psoriasis Research Study Groups: Decision Aid Testing
Psoriasis Clinical Trial 2023: Decision Aid Testing Highlights & Side Effects. Trial Name: NCT03737045 — N/A
Decision Aid Testing 2023 Treatment Timeline for Medical Study. Trial Name: NCT03737045 — N/A
~1 spots leftby Dec 2024